BioSpace News Archive

DelMar presented a poster entitled “DNA Damaging Agent Dianhydrogalactitol (VAL-083) Targets Homologous Repair (HR) Pathway and Suggests Combination Therapy with topoisomerase inhibitors and PARP inhibitors.”

Dr. Reddy’s Laboratories today announced its consolidated financial results for the second quarter and half year ended September 30, 2017 under International Financial Reporting Standards.

BioLife Solutions today announced both companies are providing their respective enhanced cold chain technologies for use in 8 active and pending clinical trials conducted by the Diabetes Center and Department of Surgery at the UCSF.

The annual ASTRO meeting was held September 24th through the 27th in San Diego, California and the annual RRS meeting was held October 15th through the 18th in Cancun, Mexico.

“In the third quarter, we continued to advance Blueprint Medicines’ broad and diversified portfolio of compelling clinical and research programs through solid execution, rigorous scientific evaluation and disciplined resource management,” said Jeff Albers, CEO of Blueprint Medicines.

Sensus Healthcare’s SRT-100 is now cleared for sale in Mexico and is approved for the treatment of non-melanoma skin cancer and keloids.

Rigel today announced that it will report its third quarter financial results after market close on Tuesday, November 7, 2017.

The collaboration will bring together Arcturus’s LUNAR lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.

Citius’ investigational program for Mino-Lok is designated “Fast Track” and is currently starting up sites for a phase III trial of Mino-Lok in the U.S.

Soligenix announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.